Table 5.
Primary outcomes for patients with PSC
| Placebo (n = 6) | Fluvoxamine (n = 5) | |||||||
| Day 0 | Day 14 | Day 42 | Day 70 | Day 0 | Day 14 | Day 42 | Day 70 | |
| VAS Fatigue | 7.3 | 7.4 | 7.5 | 8.3 | 6.4 | 6.8 | 7.5 | 7.9 |
| FFSS | ||||||||
| Physical Domain | 14 | 13 | 9 | 9 | 28 | 27 | 26 | 28 |
| Cognitive Domain | 8 | 11 | 8 | 7 | 20 | 20 | 19 | 18 |
| Social Domain | 17 | 12 | 11 | 13 | 48 | 49 | 47 | 48 |
| MFI | ||||||||
| General Fatigue | 18 | 18 | 17 | 17 | 19 | 19 | 19 | 20 |
| Physical Fatigue | 13 | 15 | 14 | 13 | 18 | 19 | 19 | 19 |
| Reduction Activity | 12 | 12 | 11 | 12 | 18 | 18 | 17 | 20 |
| Reduction Motivation | 10 | 10 | 8 | 8 | 18 | 17 | 18 | 16 |
| Mental Fatigue | 12 | 10 | 10 | 11 | 14 | 14 | 13 | 13 |
Results are expressed as median scores.